Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Used to Diagnose Polycystic Ovary Syndrome

By LabMedica International staff writers
Posted on 30 Jun 2017
An enzyme-linked immunosorbent assay (ELISA) has been developed to detect autoantibodies in polycystic ovary syndrome (PCOS), a method that could pave the way for a quicker, more efficient way to diagnose this elusive condition, where the etiology is unclear.

Medical scientists at the University of Oklahoma (Norman, OK, USA) analyzed the serum of 32 patients with PCOS based on Rotterdam criteria and 38 age and body mass index (BMI) matched, ovulatory infertile women. These included seven diagnosed with Tubal Factor (TF), 12 Male Factor (MFI), and 19 unexplained infertile women. The team hypothesized that activating autoantibodies directed to the second extracellular loop (ECL2) of the gonadotropin releasing hormone receptor (GnRHR) could be present in PCOS patients and possibly be pathogenic and of diagnostic value. Such antibodies to other G protein receptors have been found to be significant in many disorders affecting predominantly women.

The scientists identified and synthesized the 28 AA hGnRHR ECL2 loop and used this epitope target for an ELISA assay. They found a significant increase in the developed ELISA optical density in subjects with PCOS (0.26±0.07) compared to subjects with TF (0.20±0.05), subjects with MFI (0.17±0.03), and subjects with unexplained infertility (0.17±0.03). These differences were maintained regardless of the BMI. This assay demonstrated a sensitivity of 91% and a specificity of 87% for PCOS.

The authors concluded that this autoantibody targeting the second ECL of the GnRHR at the hypothalamic/pituitary level will likely be causative of the abnormal cycling shown by PCOS subjects. The present assay, with validation from their ongoing activity and blocking studies, may represent the desired serological test needed to effectively screen subjects for possible PCOS.

David C. Kem, MD, the senior investigator, said, “We’d noticed that several female patients with postural orthostatic tachycardia syndrome (POTS) had autoantibodies that activate specific receptors called G-protein coupled receptors. It dawned on me that this type of autoantibody might also be present in PCOS patients, and the likely target for that would be receptors in the pituitary gland. We noticed in the course of our work that the autoantibodies connected to these receptors were using the second extracellular loop, a part of the receptor that sticks out from the cell wall into the serum.” The study was presented at the American Association of Clinical Endocrinologists’ 26th Annual Scientific & Clinical Congress held May 3-7, 2017, in Austin, Texas.

Related Links:
University of Oklahoma


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Silver Member
ACTH Assay
ACTH ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.